Jyong Biotech showcased its botanical drug candidate Botreso® at the BIO 2026 convention, highlighting its potential to treat benign prostatic hyperplasia (BPH) and lower urinary tract symptoms. The company has completed four Phase III trials in the US and Taiwan, demonstrating safety and efficacy. With the BPH market expected to grow significantly due to aging populations and obesity, Jyong Biotech is accelerating its New Drug Application preparations and global licensing efforts to commercialize Botreso® in key markets including the US, Europe, and Asia. The company aims to expand through partnerships and strategic alliances while continuing clinical development and regulatory compliance.
LKQ Corporation announced it will publish its financial results for the second quarter of 2026 on July 30. The company will host a conference call and webcast with senior management to discuss the results, providing investors an opportunity to hear i...
First Federal Savings Bank and the Independent Community Bankers of America (ICBA) have issued 10 financial safety tips to help travelers manage their money securely during the summer travel season. Key advice includes notifying banks of travel plans...
Vivani Medical's wholly owned subsidiary Cortigent will merge with Nasdaq-listed ClearOne, which will be renamed Cortigent Holdings and trade under the ticker CRGT. Vivani will own a majority stake in the combined company, which will focus on advanci...
YD Bio Limited's U.S. affiliate, EG BioMed US, has secured clinical lab licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited lab's footprint to 46 states plus D.C. and Guam. This expansion enhances patient access to...
Diffusion, a global communications agency, is growing its home and interiors portfolio by signing new clients including POVISON (furniture), LUSA Lighting, and Induction Hardware (appliances). The agency will support these premium brands with integra...
